October 16, 2019
In the latest move to reduce its post-Shire-acquisition debt load, Takeda Pharmaceutical has struck a US$200 million-plus deal to divest some 30 non-core assets marketed in emerging markets, including non-prescription drugs, to Switzerland’s Acino. The 30-or-so products subject to the...read more